Logo image of ANEB

ANEBULO PHARMACEUTICALS INC (ANEB) Stock Fundamental Analysis

NASDAQ:ANEB - Nasdaq - US0345691036 - Common Stock - Currency: USD

1.66  -0.11 (-6.21%)

Fundamental Rating

3

Taking everything into account, ANEB scores 3 out of 10 in our fundamental rating. ANEB was compared to 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ANEB as it has an excellent financial health rating, but there are worries on the profitability. ANEB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ANEB has reported negative net income.
ANEB had a negative operating cash flow in the past year.
ANEB had negative earnings in each of the past 5 years.
In the past 5 years ANEB always reported negative operating cash flow.
ANEB Yearly Net Income VS EBIT VS OCF VS FCFANEB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ANEB has a worse Return On Assets (-54.89%) than 63.08% of its industry peers.
ANEB has a Return On Equity (-57.12%) which is in line with its industry peers.
Industry RankSector Rank
ROA -54.89%
ROE -57.12%
ROIC N/A
ROA(3y)-115.24%
ROA(5y)-105.79%
ROE(3y)-123.7%
ROE(5y)-111.36%
ROIC(3y)N/A
ROIC(5y)N/A
ANEB Yearly ROA, ROE, ROICANEB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ANEB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANEB Yearly Profit, Operating, Gross MarginsANEB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANEB has more shares outstanding
ANEB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANEB Yearly Shares OutstandingANEB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANEB Yearly Total Debt VS Total AssetsANEB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

ANEB has an Altman-Z score of 71.93. This indicates that ANEB is financially healthy and has little risk of bankruptcy at the moment.
ANEB's Altman-Z score of 71.93 is amongst the best of the industry. ANEB outperforms 98.46% of its industry peers.
ANEB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 71.93
ROIC/WACCN/A
WACCN/A
ANEB Yearly LT Debt VS Equity VS FCFANEB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

ANEB has a Current Ratio of 25.29. This indicates that ANEB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ANEB (25.29) is better than 94.87% of its industry peers.
ANEB has a Quick Ratio of 25.29. This indicates that ANEB is financially healthy and has no problem in meeting its short term obligations.
ANEB has a better Quick ratio (25.29) than 94.87% of its industry peers.
Industry RankSector Rank
Current Ratio 25.29
Quick Ratio 25.29
ANEB Yearly Current Assets VS Current LiabilitesANEB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.73% over the past year.
EPS 1Y (TTM)29.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ANEB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.26% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.56%
EPS Next 2Y-23.69%
EPS Next 3Y-13.61%
EPS Next 5Y48.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANEB Yearly Revenue VS EstimatesANEB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 2032 20M 40M 60M 80M
ANEB Yearly EPS VS EstimatesANEB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANEB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANEB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANEB Price Earnings VS Forward Price EarningsANEB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANEB Per share dataANEB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

A cheap valuation may be justified as ANEB's earnings are expected to decrease with -13.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.69%
EPS Next 3Y-13.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANEB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANEBULO PHARMACEUTICALS INC

NASDAQ:ANEB (7/11/2025, 8:00:00 PM)

1.66

-0.11 (-6.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)09-23 2025-09-23/amc
Inst Owners55.05%
Inst Owner Change0%
Ins Owners40.54%
Ins Owner Change0%
Market Cap68.19M
Analysts82.5
Price Target5.61 (237.95%)
Short Float %0.14%
Short Ratio3.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.64%
Min EPS beat(2)-10.29%
Max EPS beat(2)21.57%
EPS beat(4)2
Avg EPS beat(4)4.21%
Min EPS beat(4)-56.86%
Max EPS beat(4)62.44%
EPS beat(8)5
Avg EPS beat(8)10.82%
EPS beat(12)6
Avg EPS beat(12)4.23%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-31.25%
PT rev (3m)-31.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30%
EPS NY rev (1m)26.11%
EPS NY rev (3m)-11.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.07
P/tB 5.07
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.89%
ROE -57.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-115.24%
ROA(5y)-105.79%
ROE(3y)-123.7%
ROE(5y)-111.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.29
Quick Ratio 25.29
Altman-Z 71.93
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y7.56%
EPS Next 2Y-23.69%
EPS Next 3Y-13.61%
EPS Next 5Y48.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.58%
OCF growth 3YN/A
OCF growth 5YN/A